Home Cart Sign in  
Chemical Structure| 476310-60-8 Chemical Structure| 476310-60-8

Structure of VO-Ohpic trihydrate
CAS No.: 476310-60-8

Chemical Structure| 476310-60-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

VO-Ohpic trihydrate is a highly potent PTEN inhibitor with an IC50 of 46±10 nM.

Synonyms: VO-OHpic (hydrate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of VO-Ohpic trihydrate

CAS No. :476310-60-8
Formula : C12H11N2O9V
M.W : 378.17
SMILES Code : O[V+2]([N]1=CC=CC(O)=C1C2=O)([O-]2)([O-]C3=CC=CN=C3C4=O)([O-]4)=O.[H+].O
Synonyms :
VO-OHpic (hydrate)
MDL No. :MFCD11045907

Safety of VO-Ohpic trihydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of VO-Ohpic trihydrate

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • PTEN

    PTEN, IC50:35 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SKOV3 cells 0.1 µM VO-Ohpic reversed the antiproliferative and proapoptotic effects of EGCG on SKOV3 cells and reversed the regulation of the PTEN/AKT/mTOR pathway by EGCG. PMC7160558
Neonatal rat cardiac myocytes (NRCMs) 5 μM 24 hours VO-Ohpic trihydrate was used to inhibit PTEN activity and study its role in cardiomyocyte hypertrophy. The results showed that VO-Ohpic trihydrate significantly reversed the inhibitory effect of RES on Ang II-induced cardiomyocyte hypertrophy. PMC6226597
RKO and RKO-miR-21-KO cells 2 µM 24 hours To investigate the effect of PTEN inhibitor VO-Ohpic on AKT phosphorylation and VMP1 expression, the results showed that VO-Ohpic increased AKT phosphorylation and decreased the expression of VMP1. PMC7736343
Endothelial Progenitor Cells (EPCs) 1 μM 48 hours VO-OHpic is able to reverse the harmful effects of MPS on EPCs by inhibiting the mitochondrial apoptosis pathway and activating the Nrf2 signaling pathway, reducing apoptosis, restoring mitochondrial function, and promoting angiogenesis. PMC7106818
Neonatal rat cardiomyocytes (NRCMs) 50 nM 48 hours To evaluate the effect of VO-OHpic on autophagic flux, results showed that VO-OHpic significantly inhibited autophagic flux, as indicated by decreased autolysosomes (red) and autophagosomes (yellow). PMC10547847

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Duchenne muscular dystrophy model Intraperitoneal injection 40 mg/kg Single dose VO-Ohpic trihydrate significantly improved muscle function in mdx mice, reducing muscle fibrosis and necrotic areas PMC7791088
Mice Pressure overload-induced hypertrophic model Oral 40 mg/kg single injection VO-Ohpic trihydrate was used to inhibit PTEN activity and study its role in cardiac hypertrophy. The results showed that VO-Ohpic trihydrate significantly reversed the inhibitory effect of RES on TAC-induced cardiac hypertrophy. PMC6226597
Sprague-Dawley rats Glucocorticoid-induced osteonecrosis of the femoral head model Intraperitoneal injection 40 mg/kg Single dose 1 hour before reperfusion VO-OHpic significantly attenuates MPS-induced osteonecrosis of the femoral head, increases blood supply in the femoral head, and reduces bone resorption. PMC7106818
Mice Pressure overload-induced cardiac hypertrophy model Intraperitoneal injection 200 μg/kg Twice daily for 28 days To evaluate the effect of VO-OHpic on cardiac hypertrophy and dysfunction, results showed that VO-OHpic significantly aggravated TAC-induced cardiac hypertrophy and dysfunction and inhibited autophagy. PMC10547847

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.22mL

2.64mL

1.32mL

26.44mL

5.29mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories